The company performs assembly of technology-sensitive components and final assembly at its Maryland manufacturing facility, which currently supports production beyond anticipated demand. Processing Assemblies (PAs) are designed, developed, and shipped from headquarters, with supply and manufacturing of key PA components outsourced. Final clean-room assembly is conducted both at headquarters and by a third party. In-house cleanroom PA assembly began in 2022 to enhance quality control, capacity, and operational efficiency. The proprietary GMP-grade electroporation buffer is designed, developed, and shipped from headquarters, while production and bottling/bagging are outsourced to a third party. The company maintains relationships with multiple custom parts manufacturers and electronics suppliers, including some single-source suppliers selected for stability and scalability. Approximately 13% of inventory additions for the year ended December 31, 2025, originated from one supplier. The company holds sufficient inventory to mitigate supply chain risks and has not experienced product backorders. The supply chain is regularly assessed and diversified as the company expands.
Maxcyte Inc's Comment on Supply Chain
The company performs assembly of technology-sensitive components and final assembly at its Maryland manufacturing facility, which currently supports production beyond anticipated demand. Processing Assemblies (PAs) are designed, developed, and shipped from headquarters, with supply and manufacturing of key PA components outsourced. Final clean-room assembly is conducted both at headquarters and by a third party. In-house cleanroom PA assembly began in 2022 to enhance quality control, capacity, and operational efficiency. The proprietary GMP-grade electroporation buffer is designed, developed, and shipped from headquarters, while production and bottling/bagging are outsourced to a third party. The company maintains relationships with multiple custom parts manufacturers and electronics suppliers, including some single-source suppliers selected for stability and scalability. Approximately 13% of inventory additions for the year ended December 31, 2025, originated from one supplier. The company holds sufficient inventory to mitigate supply chain risks and has not experienced product backorders. The supply chain is regularly assessed and diversified as the company expands.
Sources:
Maxcyte inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Maxcyte inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
